Published in Vaccine Weekly, November 22nd, 1999
Indeed, many clinicians and researchers believe that success in antibacterial therapy will always depend on a steady supply of new antibacterial drugs that are unaffected by prevalent resistance mechanisms.
Decision Resources, Inc., recently published a study, titled "Emerging Antibacterial Agents," that assesses the probable efficacy of many new agents (broad-spectrum antibacterials and drugs for serious Gram-positive infections) and gives an overview...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.